Klaus Pantel, MD, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, Germany, discusses how liquid biopsies can be utilized to better individualize the treatment options for patients with lung cancer. Dr Panel highlights that this can be achieved through continuous sampling over time to monitor the molecular composition of the tumor, and to ascertain a more accurate representation of disease stage and risk assessment in these patients. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.